The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.

Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in 4Q Updated U.S. VYJUVEK label expands eligible patient population and provides ...

UD chemical engineer wins the AIChE Langer Prize for efforts to harness biology to manage plastic waste sustainably ...

Alvotech ( ($ALVO) ) has issued an update. On November 2, 2025, Alvotech announced that the U.S. FDA issued a complete response letter for its ...

The company believes the Food and Drug Administration may deal a setback to one of its investigational therapies.

Alvotech, with its strategic commercialisation partner Advanz Pharma, received EMA approval for Mynzepli (AVT06) in August ...

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer ...

Following submissions from both sides, Mohali chief judicial magistrate Megha Dhaliwal dismissed the VB’s application for ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

The modern era of biobased innovation was catalyzed by policy action. In 1999, President Bill Clinton issued Executive Order ...

University of Texas at Dallas researchers have developed biosensor technology that, when combined with artificial ...

The discovery opens a path to the sustainable synthesis of anti-inflammatory and anti-tumor agents. Scientists at UBC Okanagan have revealed how plants create mitraphylline, a rare natural substance ...